Pfizer to more than double price of its COVID antiviral once drug moves to commercial market

The listing price for Paxlovid is more than double what Pfizer charged the federal government during the COVID-19 pandemic.

Related Keywords

United States ,American ,Dave Denton ,Albert Bourla ,Us Department Of Health ,Pfizer Inc ,Human Services ,Journal Of The American Medical Association ,Pfizer ,Wall Street ,Cleveland Clinic ,American Medical Association ,Wall Street Journal ,Chief Financial Officer Dave Denton ,Article Normal ,Paxlovid ,Antiviral ,Covid19 ,Medicare ,Medicaid ,Biotechnology ,Pharmaceuticals ,Vaccines ,Wholesalers ,Retail Wholesale ,Healthcare Life Sciences ,Specialized Drugs Medications ,Antivirals ,Regulation Government Policy ,Corporate Industrial News ,Political General News ,Respiratory Tract Diseases ,Health ,Medical Conditions ,Outbreaks Epidemics ,Novel Coronaviruses ,Infectious Diseases ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Pfe ,Regulation ,Government Policy ,Corporate ,Industrial News ,Political ,General News ,Outbreaks ,Epidemics ,Retail ,Wholesale ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,